Device Week, April 3, 2020 – New Telemonitoring Patch; Medtronic Delays Renal Denervation Approval
Executive Summary
In this edition of the Device Week podcast, Medtech Insight managing editor Marion Webb discusses LifeSignals’ plans for a vital-sign monitoring patch that could help remotely monitor patients during the pandemic. Deputy editor Reed Miller highlights some important device trials presented at the American College of Cardiology online conference.
You may also be interested in...
LifeSignals Plans To Market Biosensor Patch To Help Consumer Identify COVID-19 Symptoms
LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19.
Grail’s Liquid Biopsy Can Detect Numerous Deadly Cancer Types Early
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Approval Of Medtronic’s Renal Denervation System Delayed By COVID-19
Medtronic says that most of the clinical trials it is sponsoring are paused due to the pandemic, which means the completion of its PMA application for the Symplicity Spyral renal denervation system will be delayed.